TY - JOUR
T1 - Paraoxonase 1 and atherosclerosis-related diseases
AU - Kotur-Stevuljević, Jelena
AU - Vekić, Jelena
AU - Stefanović, Aleksandra
AU - Zeljković, Aleksandra
AU - Ninić, Ana
AU - Ivanišević, Jasmina
AU - Miljković, Milica
AU - Sopić, Miron
AU - Munjas, Jelena
AU - Mihajlović, Marija
AU - Spasić, Slavica
AU - Jelić-Ivanović, Zorana
AU - Spasojević-Kalimanovska, Vesna
N1 - Funding Information:
This work was financially supported by grant from the Serbian Ministry of Education, Science and Technological Development (project number 175035). The study funder had no role in study design, analysis, interpretation of data, and writing of the manuscript; nor in the decision to submit the manuscript for publication. We want to thank Dr. David R. Jones for his excellent help in English language correction and critical revision of the manuscript.
Publisher Copyright:
© 2019 International Union of Biochemistry and Molecular Biology
PY - 2020/3/1
Y1 - 2020/3/1
N2 - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.
AB - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.
KW - atherosclerosis
KW - cancer
KW - cardiovascular disease
KW - diabetes
KW - HDL dysfunction
KW - paraoxonase 1
KW - renal disease
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85070335419&partnerID=8YFLogxK
U2 - 10.1002/biof.1549
DO - 10.1002/biof.1549
M3 - Review article
C2 - 31400246
AN - SCOPUS:85070335419
SN - 0951-6433
VL - 46
SP - 193
EP - 205
JO - BioFactors
JF - BioFactors
IS - 2
ER -